메뉴 건너뛰기




Volumn 30, Issue 4, 2013, Pages

Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement

Author keywords

CD20; CLL; Complement; Non Hodgkin's lymphoma; Ofatumumab; Rituximab

Indexed keywords

CD20 ANTIGEN; COMPLEMENT; COMPLEMENT INHIBITOR; DECAY ACCELERATING FACTOR; OFATUMUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

EID: 84886816138     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0759-5     Document Type: Article
Times cited : (23)

References (19)
  • 1
    • 70450265301 scopus 로고    scopus 로고
    • Complement: Coming full circle
    • 10.1007/s00005-009-0047-4
    • Friec GL, Kemper C. Complement: coming full circle. Arch Immunol Ther Exp (Warsz). 2009;57(6):393-407.
    • (2009) Arch Immunol Ther Exp (Warsz) , vol.57 , Issue.6 , pp. 393-407
    • Friec, G.L.1    Kemper, C.2
  • 2
    • 1542357604 scopus 로고    scopus 로고
    • Identification of tumor antigens and T-cell epitopes, and its clinical application
    • DOI 10.1007/s00262-003-0479-3
    • Paschen A, Eichmuller S, Schadendorf D. Identification of tumor antigens and T-cell epitopes, and its clinical application. Cancer Immunol Immunother. 2004;53(3):196-203. (Pubitemid 38328042)
    • (2004) Cancer Immunology, Immunotherapy , vol.53 , Issue.3 , pp. 196-203
    • Paschen, A.1    Eichmuller, S.2    Schadendorf, D.3
  • 3
    • 0022982447 scopus 로고
    • Membrane alterations in cancer cells: The role of oxy radicals
    • 3555261 10.1111/j.1749-6632.1986.tb46579.x 1:CAS:528:DyaL2sXkvFCnsbg%3D
    • Galeotti T, Borrello S, Minotti G, Masotti L. Membrane alterations in cancer cells: the role of oxy radicals. Ann N Y Acad Sci. 1986;488:468-80.
    • (1986) Ann N y Acad Sci , vol.488 , pp. 468-480
    • Galeotti, T.1    Borrello, S.2    Minotti, G.3    Masotti, L.4
  • 5
    • 84878919900 scopus 로고    scopus 로고
    • Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies
    • 23219151 10.1016/j.ctrv.2012.10.008 1:CAS:528:DC%2BC38Xhsl2ju7vI
    • Okroj M, Osterborg A, Blom AM. Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies. Cancer Treat Rev. 2013;39(6):632-9.
    • (2013) Cancer Treat Rev , vol.39 , Issue.6 , pp. 632-639
    • Okroj, M.1    Osterborg, A.2    Blom, A.M.3
  • 6
    • 79955011744 scopus 로고    scopus 로고
    • Molecular mechanisms of the antitumor effects of anti-CD20 antibodies
    • 10.2741/3688
    • Winiarska M, Glodkowska-Mrowka E, Bil J, Golab J. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci. 2010;16:277-306.
    • (2010) Front Biosci , vol.16 , pp. 277-306
    • Winiarska, M.1    Glodkowska-Mrowka, E.2    Bil, J.3    Golab, J.4
  • 7
    • 0042236333 scopus 로고    scopus 로고
    • Rituximab in B-cell chronic lymphocytic leukemia
    • DOI 10.1016/S0093-7754(03)00239-2
    • Lin TS, Lucas MS, Byrd JC. Rituximab in B-cell chronic lymphocytic leukemia. Semin Oncol. 2003;30(4):483-92. (Pubitemid 36999690)
    • (2003) Seminars in Oncology , vol.30 , Issue.4 , pp. 483-492
    • Lin, T.S.1    Lucas, M.S.2    Byrd, J.C.3
  • 8
    • 0035760902 scopus 로고    scopus 로고
    • CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: Further regulation by CD55 and CD59
    • 11719378 10.1182/blood.V98.12.3383 1:CAS:528:DC%2BD3MXovVSgsb8%3D
    • Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 2001;98(12):3383-9.
    • (2001) Blood , vol.98 , Issue.12 , pp. 3383-3389
    • Golay, J.1    Lazzari, M.2    Facchinetti, V.3    Bernasconi, S.4    Borleri, G.5    Barbui, T.6
  • 9
    • 79952278698 scopus 로고    scopus 로고
    • Ofatumumab: A new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia
    • 21030349 10.3816/CLML.2010.n.069
    • O'Brien S, Osterborg A. Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2010;10(5):361-8.
    • (2010) Clin Lymphoma Myeloma Leuk , vol.10 , Issue.5 , pp. 361-368
    • O'Brien, S.1    Osterborg, A.2
  • 10
    • 84871831846 scopus 로고    scopus 로고
    • Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy
    • 23225880 10.4049/jimmunol.1202645 1:CAS:528:DC%2BC38XhvV2ks7%2FI
    • Bologna L, Gotti E, Da Roit F, Intermesoli T, Rambaldi A, Introna M, et al. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J Immunol. 2013;190(1):231-9.
    • (2013) J Immunol , vol.190 , Issue.1 , pp. 231-239
    • Bologna, L.1    Gotti, E.2    Da Roit, F.3    Intermesoli, T.4    Rambaldi, A.5    Introna, M.6
  • 11
    • 84859402731 scopus 로고    scopus 로고
    • Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients
    • 22368276 10.4049/jimmunol.1103693 1:CAS:528:DC%2BC38XksVOltbw%3D
    • Beurskens FJ, Lindorfer MA, Farooqui M, Beum PV, Engelberts P, Mackus WJ, et al. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol. 2012;188(7):3532-41.
    • (2012) J Immunol , vol.188 , Issue.7 , pp. 3532-3541
    • Beurskens, F.J.1    Lindorfer, M.A.2    Farooqui, M.3    Beum, P.V.4    Engelberts, P.5    Mackus, W.J.6
  • 12
    • 84878909091 scopus 로고    scopus 로고
    • Investigation of the factors that influence complement-dependent cytotoxicity (CDC) following ofatumumab treatment in chronic lymphocytic leukaemia
    • Middleton O, Cosimo E, Dobbin E, McCaig AM, Clarke C, Brant AM, et al. Investigation of the factors that influence complement-dependent cytotoxicity (CDC) following ofatumumab treatment in chronic lymphocytic leukaemia. Immunology. 2012;137(Suppl. 1):196.
    • (2012) Immunology , vol.137 , Issue.SUPPL. 1 , pp. 196
    • Middleton, O.1    Cosimo, E.2    Dobbin, E.3    McCaig, A.M.4    Clarke, C.5    Brant, A.M.6
  • 13
    • 84865367405 scopus 로고    scopus 로고
    • Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma
    • 10.1002/ajh.23273 22718493 10.1002/ajh.23273 1:CAS:528:DC%2BC38Xht1ekt7zP
    • Charbonneau B, Maurer MJ, Fredericksen ZS, Zent CS, Link BK, Novak AJ, et al. Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma. Am J Hematol. 2012;87(9):880-5. doi: 10.1002/ajh.23273.
    • (2012) Am J Hematol , vol.87 , Issue.9 , pp. 880-885
    • Charbonneau, B.1    Maurer, M.J.2    Fredericksen, Z.S.3    Zent, C.S.4    Link, B.K.5    Novak, A.J.6
  • 14
    • 84867391087 scopus 로고    scopus 로고
    • Functional analyses of complement convertases using C3 and C5-depleted sera
    • 23071769 10.1371/journal.pone.0047245 1:CAS:528:DC%2BC38XhsFOku7fP
    • Okroj M, Holmquist E, King BC, Blom AM. Functional analyses of complement convertases using C3 and C5-depleted sera. PLoS ONE. 2012;7(10):e47245.
    • (2012) PLoS ONE , vol.7 , Issue.10 , pp. 47245
    • Okroj, M.1    Holmquist, E.2    King, B.C.3    Blom, A.M.4
  • 15
    • 84856249903 scopus 로고    scopus 로고
    • Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma
    • 22150234 10.1111/j.1365-2141.2011.08966.x 1:CAS:528:DC%2BC38Xks1yisb8%3D
    • Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai PC, Gibbs JF, Deeb G, et al. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Br J Haematol. 2012;156(4):490-8.
    • (2012) Br J Haematol , vol.156 , Issue.4 , pp. 490-498
    • Barth, M.J.1    Hernandez-Ilizaliturri, F.J.2    Mavis, C.3    Tsai, P.C.4    Gibbs, J.F.5    Deeb, G.6
  • 16
    • 80455162357 scopus 로고    scopus 로고
    • RILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia
    • 21918174 10.1158/1078-0432.CCR-11-0647 1:CAS:528:DC%2BC3MXhsVWlsr7E
    • Ge X, Wu L, Hu W, Fernandes S, Wang C, Li X, et al. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clin Cancer Res. 2011;17(21):6702-11.
    • (2011) Clin Cancer Res , vol.17 , Issue.21 , pp. 6702-6711
    • Ge, X.1    Wu, L.2    Hu, W.3    Fernandes, S.4    Wang, C.5    Li, X.6
  • 17
    • 0034660092 scopus 로고    scopus 로고
    • Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
    • Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95(12):3900-8. (Pubitemid 30412866)
    • (2000) Blood , vol.95 , Issue.12 , pp. 3900-3908
    • Golay, J.1    Zaffaroni, L.2    Vaccari, T.3    Lazzari, M.4    Borleri, G.-M.5    Bernasconi, S.6    Tedesco, F.7    Rambaldi, A.8    Introna, M.9
  • 18
    • 33644866786 scopus 로고    scopus 로고
    • Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines
    • DOI 10.1016/j.leukres.2005.09.008, PII S0145212605003607
    • Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leuk Res. 2006;30(5):625-31. doi: 10.1016/j.leukres.2005.09.008. (Pubitemid 43374591)
    • (2006) Leukemia Research , vol.30 , Issue.5 , pp. 625-631
    • Takei, K.1    Yamazaki, T.2    Sawada, U.3    Ishizuka, H.4    Aizawa, S.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.